It does make me not hungry which is the best part
NICE technology appraisals: semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight management
[28] Other side effects reported were dyspepsia, constipation, abdominal pain, dizziness, and hypoglycemia
It simultaneously activates three key metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and the receptor at glucagon This triple synergistic action makes it one of the most studied peptides in research on obesity and metabolic disorders
Prior authorization : With prior authorization, your healthcare professional must submit documentation to the insurance plan
GLP-1 therapy requires sustained monitoring for pancreatitis risk, dehydration, rapid weight loss complications, and medication interactions